Migraine Headache in an Employed Population: Demographics, Health Risks, Pharmaceutical Utilization, and Productivity Loss

J Occup Environ Med. 2022 Aug 1;64(8):679-685. doi: 10.1097/JOM.0000000000002564. Epub 2022 Jun 9.

Abstract

Objective: Demographics, health risks, pharmaceutical utilization, and other characteristics of adults with and without migraine who were employed by a school district in the southern United States were compared.

Methods: A total of 4528 employees completed a health risk appraisal. A diagnosis of migraine was reported by 11%. Employees with and without migraine were compared on several measures.

Results: Demographic and health risk differences were observed among the comparison groups. One-fifth of migraineurs had a prescription for an opioid, which was associated with very high average annual health care costs ($17,791) compared with migraineurs without opioid ($3907).

Conclusions: Migraine is common in the workforce. Employers may want to educate employees with migraine about evidence-based treatments. Benefit plan design should be consistent with current accepted treatment guidelines for opioid use.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analgesics, Opioid* / therapeutic use
  • Demography
  • Efficiency
  • Humans
  • Migraine Disorders* / drug therapy
  • Migraine Disorders* / epidemiology
  • Pharmaceutical Preparations
  • United States / epidemiology

Substances

  • Analgesics, Opioid
  • Pharmaceutical Preparations